Collectively, our data identify novel peptide-based inhibitors of cathepsin G or elastase and demonstrate proof-of-principle that such inhibitors might have potential as antagonists of IL-36 cytokine activation in disease settings, such as psoriasis, that are associated with elevated IL-36 cytokine activity. Here, CTSG is linked to psoriasis.